Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entacapone + levodopa + carbidopa
- Development stage
- Unknown
- Lead developer
- Orion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The drug is a generic fixed-dose combination of entacapone, levodopa, and carbidopa, specifically the 'Tablets (II)' formulation produced by Qilu Pharmaceutical. It is used for the treatment of Parkinson's disease, particularly in patients experiencing 'wearing-off' symptoms. Levodopa serves as a metabolic precursor to dopamine, which is depleted in Parkinson's disease. Carbidopa is an aromatic L-amino acid decarboxylase (AADC) inhibitor that prevents the peripheral conversion of levodopa to dopamine, thereby reducing side effects and increasing the amount of levodopa that reaches the brain. Entacapone is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor that further blocks the peripheral metabolism of levodopa into 3-O-methyldopa, extending the plasma half-life of levodopa and enhancing its brain bioavailability. This specific entry refers to a bioequivalence study conducted by The Affiliated Hospital of Qingdao University to compare this generic version against the reference listed drug, Stalevo.
- Other names
- Entacapone, Levodopa and Carbidopa Tablets (II)entacapone/levodopa/carbidopa
02
Targets
DDC (Aromatic L-amino acid decarboxylase)COMT (Catechol-O-methyltransferase)
Beyond the preview
Go deeper on entacapone + levodopa + carbidopa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entacapone + levodopa + carbidopa.